MedWatch

Bank predicts double blockbuster status for Novo obesity drug next year

Novo Nordisk's weight loss drug Wegovy could be heading for double blockbuster status as soon as next year, according to an analysis by Danske Bank, which has almost doubled its previous expectations for the medicine.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The obesity drug Wegovy, developed by Novo Nordisk, could reach double blockbuster status as soon as next year, estimates an analysis from Danske Bank, reports media PLX.AI.

A blockbuster drug is industry terminology for a drug exceeding USD 1bn in sales annually. This latest estimation from Danske Bank is almost twice its earlier expectations for the medicine.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs